Moffitt Cancer Center | Strategic Alliance Partners

Jonathan R. Strosberg, MD, reviews the clinical implications of PRRT with 177Lu-edotreotide for metastatic gastroenteropancreatic neuroendocrine tumors.

Lodovico Balducci, MD, built a new discipline from the ground up, which kick-started pivotal research in geriatric oncology.

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for recurrence.

Robert Emmons, MD, FACP, Joshua Brody, MD, and Javier Pinilla, MD, PhD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in chronic lymphocytic leukemia and lymphoma presented during the 2025 ASH Annual Meeting & Exposition.

Roger Li, MD, discusses progression risk in low-grade NMIBC and how AI-based pathology tools may improve identification of patients at risk for high-grade disease.

Investigators at Moffitt Cancer Center have developed a novel biomaterial-based system that induces the formation of tertiary lymphoid-like structures.

212Pb-DOTAMTATE produced responses with a manageable safety profile in patients with SSTR-positive, PRRT-exposed, unresectable or metastatic GEP-NETs.

Real-world MCL treatment with zanubrutinib generated longer treatment durations and higher treatment adherence rates vs acalabrutinib and ibrutinib.

The top 5 OncLive TV videos of the week cover insights in lung cancer, and prostate cancer, myelofibrosis.

Andrew Kuykendall, MD, discussed the advantages and limitations of using QOL- and symptom-related end points in myelofibrosis clinical research.

Andrew Kuykendall, MD, provides an overview of the myelofibrosis treatment paradigm.

Zeynep Eroglu, MD, discusses the implications of using triplet vs doublet regimens in patients with melanoma who have symptomatic brain metastases.

Jad Chahoud, MD, MPH, discusses the CAR T-cell therapy ALLO-316 in advanced clear cell renal carcinoma (ccRCC).

Ahmad Tarhini, MD, PhD, discussed the rationale for evaluating preoperative pembrolizumab plus vidutolimod in macroscopic, resectable stage III melanoma.

Drs Logan and Shah discussed where obe-cel currently fits into the B-ALL treatment paradigm and how the use of this agent might expand going forward.

Bijal Shah, MD, MS, discusses key safety and efficacy outcomes from a post hoc analysis of the FELIX trial of obe-cel in relapsed/refractory B-ALL.

Rami Komrokji, MD, shares advice on how to integrate imetelstat into clinical practice for transfusion-dependent lower-risk myelodysplastic syndromes.

Oncology experts share topline insights from 19 of the most exciting abstracts from the 2025 ASCO Annual Meeting.

Ou Deng, PhD, discussed findings from a study investigating MSH6-modulated PARP inhibitor sensitivity in BRCA-proficient, high-grade serous ovarian cancer.

Bijal Shah, MD, MS, and Jae Park, MD, discuss quality-of-life data for obe-cel in acute lymphoblastic leukemia.

Bijal Shah, MD, MS, and Jae Park, MD, discuss other key data in acute lymphoblastic leukemia from EHA 2025.

Bijal Shah, MD, MS, and Jae Park, MD, discuss how inotuzumab exposure may influence response to obe-cel in ALL.

Bijal Shah, MD, MS, and Jae Park, MD, predictors of sustained remission with obe-cel in acute lymphoblastic leukemia.

Bijal Shah, MD, MS, and Jae Park, MD, discuss an age-based analysis of outcomes with obe-cel in acute lymphoblastic leukemia.

Bijal Shah, MD, MS, and Jae Park, MD, discuss how the integration of obe-cel has affected the acute lymphoblastic treatment paradigm.

Rami Komrokji, MD, shares results from a pooled analysis of outcomes with imetelstat based on prior therapy in transfusion-dependent lower-risk MDS.

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a potential new therapy.

Andrew Kuykendall, MD, discusses responses with rusfertide for patients with phlebotomy-dependent polycythemia vera.

Rami Komrokji, MD, discusses the evolution of lower-risk MDS treatments that reflect novel classification systems and trials exploring novel therapies.

Rami Komrokji, MD, discusses several trials that supported the FDA approval of luspatercept for the treatment of patients with MDS with anemia.